Completion capital for a regulated pharmaceutical cannabis production asset
Planning secured. c.17,000 sq ft initial indoor site with scalable potential to 100,000+ sq ft. Positioned for UK prescription supply with Northern Ireland strategic optionality.
Planning secured - Site identified - Completion capital sought
At a glance
Planning permission secured for change of use and facility development
c.17,000 sq ft initial indoor site with scalable footprint to 100,000+ sq ft
Completion capital sought for fit-out, licensing progression and first commercial production
UK compliance story with Northern Ireland strategic optionality for GB and EU goods movement context
Completion capital to deliver a licensed production site in Northern Ireland with UK-regulated credibility and wider platform optionality.
Strategic Asset. Growth Industries is developing a licensed controlled-drug pharmaceutical production facility within the UK regulatory framework. The value of the asset comes from licensing, secure infrastructure and compliance capability - not agricultural production alone.
The UK medical cannabis market is defined by regulation, not agriculture
Demand is growing through specialist clinics and pharmacies, but compliant domestic production remains limited. That leaves a structurally import-led supply chain - and a clear opening for controlled UK supply.
80,000+
Patients expected to exceed 80,000 in 2026
Illustrative market signal for concept only.
15t+
Imported flower in 2024
Highlights the import-led structure of the UK channel.
2018
Medical cannabis legal in the UK
The private prescribing channel exists and continues to mature.
Imported supply vs domestic production
Imported supply leaves the market dependent on external logistics and release timing.
Domestic production improves traceability, reliability and regulatory control.
Strategic value sits in compliant capacity inside the UK framework.
Regulatory barrier
Why this asset exists
Barriers to entry are regulatory, operational and capital intensive.
1
Home Office
Controlled-drug licensing, site security and inspection requirements.
2
MHRA
Manufacturing oversight, systems discipline and inspection readiness.
3
GACP / GMP
Quality, traceability, documentation and repeatable batch control.
4
Security + release
Access control, audit trail and compliant release discipline.
Northern Ireland advantage
A UK-regulated asset with strategic optionality
Northern Ireland adds a differentiated location story to a UK-compliant production asset.
The message is subtle: a serious UK compliance story with a more interesting jurisdictional position than a plain mainland site.
The site
Planning secured, premises identified, scalable footprint
The physical site makes the story more tangible. Investor capital therefore completes a real project rather than funding a concept-stage venture.
Planning granted
24 May 2024
Reference
Available on Request
Initial indoor footprint
c.17,000 sq ft
Asset type
High-security, climate-controlled premises
Route to Market
Licensed B2B supply, not retail cannabis
Facility
→
Licensed distributor
→
Pharmacy
→
Patient
Phase 1 revenue comes through existing licensed UK supply channels - not consumer branding or direct retail.
Leadership
Relevant experience in regulated environments
Gareth Dundee Founder
Regulated-project operator with experience in highly controlled environments and Northern Ireland industry representation.
Mark Judge Operations
Medical logistics, controlled-drug transfer and facility management experience.
Peter Reynolds Strategy and Communications
Experienced policy and medical-communications operator with long-standing sector knowledge.
Jamie Oduro Quality and Compliance
GACP, GMP and pharmaceutical quality systems specialist with licensing and inspection-readiness experience.
Paul Shrive Cultivation/ Production
Over a decade in cannabinoid processing and cultivation expertise developed in the USA.
Jonathan Potter Clinical Research
BA, MSC, DIP.Couns, PGDIPClinical psychologist with more than 20 years of therapeutic experience including medical cannabis.
Investment opportunity
Planning secured for the premises
Import-led market with growing patient access
Licensed B2B route to market
Northern Ireland strategic positioning
Founder capital already committed
Regulatory barriers limit compliant domestic sites